Industry Focus - CG: Truth About the Retail Apocalypse

CG: Truth About the Retail Apocalypse

02/18/20 • 33 min

Dan Kline joins Emily Flippen to debunk the myth of the “retail apocalypse” , what he sees as driving the sector's underperformance, and what could have gone different to save the industry.

Check out more of our content here:

To get 50% off our Stock Advisor service, go to https://IF.Fool.com

Dan Kline joins Emily Flippen to debunk the myth of the “retail apocalypse” , what he sees as driving the sector's underperformance, and what could have gone different to save the industry.

Check out more of our content here:

To get 50% off our Stock Advisor service, go to https://IF.Fool.com

Previous Episode

Tech: Regulators Weigh In

Investors finally have closure on the Sprint/T-Mobile deal, we explain the decision, what it says about Sprint and T-Mobile, and what it all means for major Sprint shareholder Softbank. Then we switch gears and talk about the FTC's new focus on small acquisitions made over the past few years by Apple, Amazon, Google, and Microsoft.

Stocks: AAPL, AMAN, GOOG, GOOGL, MSFT, TMUS, S

Check out more of our content here:

Get the first $50 off your first job post at LinkedIn.com/fool. Terms and conditions apply.

Next Episode

Wildcard: 3 Diabetes Dynamos

One in seven healthcare dollars in the United States are spent on diabetes and its related complications. That’s a huge burden for patients and for insurance companies. Thankfully, businesses are working to improve the outcomes for patients. Industry Focus Contributor Brian Feroldi joins the show to dive into three companies trying to improve diabetes treatment and monitoring: Dexcom, Tandem Diabetes, and Insulet.

Check out more of our content here:

Stocks Discussed: DXCM, TNDM, PODD

Click here to take our brief listener survey, and thanks for helping us out!